KRUNJA / SHUTTERSTOCK.COM
Over the past few years China’s life sciences sector has become a hive of activity as specialist IP courts have been implemented and M&A activity has ramped up. LSIPR assesses some of these developments.
In 2014, three specialist intellectual property courts were established in Beijing, Shanghai and Guangzhou.
Within eight months, the courts had received more than 10,000 lawsuits and decided 4,160 cases, according to a press conference by the Supreme People’s Court of China, reported on by Lee and Li Attorneys-at-Law.
James Zhu, partner at law firm JunHe, applauds the progress made by the Chinese courts in the IP arena over the past few years.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Eli Lilly, Roche, life sciences, Chinese Food and Drug Administration, IP enforcement, M&A, patent, licensing, GE Healthcare,
